COMMUNIQUÉS West-GlobeNewswire

Inventiva publie ses résultats financiers non audités du premier semestre 2026 et fait le point sur ses activités
28/09/2026
Trésorerie et équivalents de trésorerie à 166,1 millions d’euros et dépôts à court terme 1 à 67,8 millions d’euros au 30 juin 2026 Horizon de trésorerie inchangé par rapport au 30 juillet 2026 2 Résultats principaux de [...]
Inventiva Reports Unaudited 2026 First-Half Financial Results and Provides Corporate Update
28/09/2026
Cash and cash equivalents at €166.1 million and €67.8 million in short-term deposits 1 as of June 30, 2026 Cash runway guidance remains unchanged from July 30, 2026 2 Topline results of the Phase 3 NATiV3 clinical trial [...]
Unlocking the Growth - Invitation to BioPorto’s investor meeting on October 7
28/09/2026
September 28, 2026 News release Unlocking the Growth - Invitation to BioPorto’s investor meeting on October 7 As BioPorto continues to advance its commercial strategy and capitalize on emerging clinical opportunities, [...]
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
28/09/2026
COPENHAGEN, Denmark, September 28, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on September 1, 2026, under which the Company will repurchase shares for an [...]
Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Opamtistomig (LBL-024) Granted Orphan Drug Designation in Japan, Further Expanding Global Regulatory Recognition
28/09/2026
NANJING, China, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that opamtistomig (LBL-024), the Company’s proprietary PD‑L1/4‑ [...]
Thermo Fisher Scientific and Evosep Enter Reseller Agreement for Evosep Eno
28/09/2026
Thermo Fisher Scientific to offer the Evosep Eno separation platform to customers, expanding access to standardized, high-throughput proteomics workflows SINGAPORE, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Evosep™, a global [...]
A New International Medical Approach Aimed at Reversing Diabetes has Officially Launched in Shenzhen, China
28/09/2026
SHENZHEN, China, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Recently in Shenzhen, China, the Center for Integrative Medicine for Chronic Diseases and the Center for Natural Diabetes Therapy at Shenzhen Hengsheng Hospital—a [...]
Penn Medicine et IBA lancent une joint-venture pour accompagner le développement de la protonthérapie et des programmes de radio-oncologie dans le monde
28/09/2026
Une nouvelle offre de services d’experts afin d’aider les établissements de santé à développer, déployer et optimiser leurs programmes de protonthérapie et de radio-oncologie sur l’ensemble des soins PHILADELPHIE, [...]
Penn Medicine and IBA Launch Joint Venture to Advance Proton Therapy and Radiation Oncology Program Development Worldwide
28/09/2026
New expert-led services platform will help healthcare providers develop, implement, and optimize proton therapy and advanced radiation oncology programs across the full care delivery lifecycle PHILADELPHIA, Pa., and [...]
Addex Therapeutics Reports 2026 Half-Year Results and Provides Corporate Update
28/09/2026
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 28, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small [...]
JJP Biologics to Present Data Showing the Potential of Nebaprubart for Linear IgA Dermatosis (LAD) at Two Key Upcoming Scientific Conferences
28/09/2026
Positive interim data from Phase Ib proof-of-concept trial will be presented at the IPPF Scientific Symposium on Pemphigus and Pemphigoid and at EADV Congress 2026 Data positions nebaprubart as a potential therapy [...]
OSE Immunotherapeutics publie sa position de trésorerie au 30 juin 2026 et fait un point sur ses activités
28/09/2026
11,1 millions d’euros de trésorerie au 30 juin 2026 ; horizon de financement confirmé jusqu’à fin décembre 2026 La Société poursuit activement ses interactions avec les investisseurs institutionnels aux États-Unis et en [...]
OSE Immunotherapeutics Reports its Cash Position as of June 30, 2026, and Provides Business Update
28/09/2026
€11.1 million cash position as of June 30, 2026; cash runway confirmed through December 2026 The Company continues to engage actively with institutional investors in the United States and Europe to extend its cash [...]
HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors
28/09/2026
First-in-class KRAS-payload leveraging synchronized EGFR inhibition HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 27, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ” or the “Company”) (Nasdaq/AIM: [...]
ITM and Lumara Bio Announce Real-World Re-treatment Data and Dosimetry Results from COMPETE for ¹⁷⁷Luedotreotide (ITM-11) in GEP-NETs at ASTRO 2026
27/09/2026
Investigator-led SwissNET registry analysis showed longer real-world progression-free and overall survival for patients re-treated with 177 Lu-edotreotide compared to those receiving non-radiopharmaceutical systemic [...]
IBA lance le fantôme QUASAR® Penta-Guide Performance
27/09/2026
Plus de 25 tests d'imagerie et de contrôle qualité machine réunis en une seule configuration. Louvain-la-Neuve, Belgique, 27 septembre 2026 – IBA (Ion Beam Applications S.A., EURONEXT), leader mondial de la technologie [...]
IBA Launches QUASAR® Penta-Guide Performance Phantom
27/09/2026
More than 25 imaging and machine QA tests in one setup. Louvain-la-Neuve, Belgium, 27 September 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and a global [...]
TamaBio to Showcase Synthetic Biomembrane Technology at ACS Clinical Congress 2026 in Washington, D.C.
27/09/2026
Japanese medical technology company will introduce U.S. surgeons and industry partners to its DuraBeam® and PeriBeam® devices WASHINGTON, Sept. 27, 2026 (GLOBE NEWSWIRE) -- TamaBio Company Limited , a Japanese medical [...]
The Future of Radiotherapy is Here: Siemens Healthineers Launches Accela
27/09/2026
The Accela radiotherapy solution is engineered around NeoArc dynamic modulated arc therapy (DMAT), a breakthrough technique combining speed and precision Boston, Sept. 27, 2026 (GLOBE NEWSWIRE) -- Siemens Healthineers [...]

Pages